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Abstract
The impact of aging on healthcare expenditure (HCE) has been at the center of a prolonged de-
bate. This paper purports to shed light on several issues of this debate by presenting new evidence
on the “red herring” hypothesis advanced by Zweifel, Felder and Meier (1999). This hypothe-
sis amounts to distinguishing a mortality from a morbidity component in healthcare expenditure
(HCE) and claiming that failure to make this distinction results in excessive estimates of future
growth of HCE. A re-estimation based on a much larger data set is performed, using the refined
econometric methodology. The main contribution is consistency, however. Rather than treating
the mortality component as a residual in forecasting, its dynamics are analyzed in the same detail
as that of the morbidity component when predicting the impact of population aging on the future
growth of HCE. For the case of Switzerland, it finds this impact to be relatively small regard-
less of whether or not the mortality component is accounted for, thus qualifying the ”red herring”
hypothesis.
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1 Introduction
Economic progress and advances of medical technology have enhanced both
standards of living and effectiveness of health care in the industrialized world,
resulting in an enormous increase of life expectancy. In addition, fertility
rates have been dropping since the end of the so-called baby boom in the late
1960s. These two trends in combination cause a marked aging of population,
i.e. the share of the elderly will increase dramatically in the two decades to
come.
Since there is a strong cross-section relationship between age and per
capita healthcare expenditure (henceforth HCE) at the individual level, ag-
ing populations are often predicted to have increasing costs of health at the
population level. However, the econometric evidence is ambiguous. Only
two cross-national studies find the age structure of developed countries to be
a consistently significant predictor of HCE [cf. Hitiris and Posnett (1992)
and Gerdtham, Søgaard, Jo¨nsson and Andersson (1992b)]. Using a variety
of econometric specifications, many other studies conclude that age is not
significantly related to per capita HCE [cf. Gerdtham, Søgaard, Andersson
and Jo¨nsson (1992a); Gerdtham, Jo¨nsson, MacFarlan and Oxley (1998); Get-
zen (1992); Leu (1986); O’Connell (1996); OECD (1987); Zweifel, Steinmann
and Eugster (2005)].
One explanation that has been advanced is that the cross-section rela-
tionship between age and HCE fails to control for an important variable
that has varied in the past and may continue to vary in the future, viz. the
share of the population approaching death. Individuals approaching death
usually suffer deterioration of their health status, which is known to trigger
HCE [cf. Guralnik, LaCroix, Branch, Kasl and Wallace (1991)]. Unfortu-
nately, health status is hardly ever measured by health insurers. In view
of the strong correlation between health and time to death, Lee and Miller
(2002) conclude that time to death (TTD) is a reasonable indicator of health
status, especially when the objective is to project future HCE.
Much of the increase of average HCE with age evidenced by health insur-
ers may be due to the fact that the share of the deathbound rises substantially
at higher ages, resulting in a changing composition of the insured popula-
tion. According to several studies, TTD goes along with a marked surge
in HCE [cf. Lubitz and Prihoda (1984), Lubitz, Beebe and Baker (1995)].
This means that average HCE is increasingly influenced by a group whose
HCE is multiples of that of survivors. Lubitz and Prihoda (1984) estimate
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that the 5.1 percent of Medicare recipients dying in a given year account for
no less than 29 percent of total HCE. This finding seems to be quite stable
over time, as evidenced by Lubitz and Riley (1993) and Barnato, Garber,
Kagay and McClellan (2006).
In the course of aging over time, two effects need to be distinguished.
First, individuals will simply enter the costly final year of their lives at a
later age. Aging thus amounts to a ’red herring’ when it comes to predicting
future HCE (Zweifel et al. (1999), ZFM henceforth). Second, however, the
composition of the population will change in favor of a larger share of indi-
viduals close to death due to the baby-boomers. As a result, average HCE
may increase in spite of the ’red herring’ argument.
More generally, HCE needs to be split into what may be called a morbid-
ity component and a mortality component. While the morbidity component
is spent on the survivors, the mortality component is spent on the death-
bound only. The role of age in this distinction cannot be determined at a
given point in time, since higher age and TTD are the same. In the course
of time, however, this needs not to be true. In order to test for the impact
of aging on these two components of HCE, three concepts of time have to
be distinguished. Historical time (the year of observation) reflects the state
of medical technology; time from birth (the age of the individual) stands for
the effect of age on the morbidity component (uncorrelated with mortality);
and TTD determines the mortality component of HCE, which can only be
identified with independent information about remaining life expectancy.
Using panel data on deceased members of two Swiss social health insurers
covering the years 1983 to 1994, ZFM were the first to be able to separate
these three concepts of time. Relating quarterly HCE to sex, type of insur-
ance, age, proximity to death, and year of observation, they found age not to
be a significant determinant of HCE during the last two years of life, at least
for the population aged 65 and above. On the other hand, TTD was highly
significant, with its estimated effect on HCE consistently increasing with
TTD. Extending TTD to cover as much as the last five years of life, ZFM
found these findings to be confirmed, leading them to argue that aging will
not affect HCE growth when controlling for proximity to death (and hence
the mortality component of HCE). For them, aging is a ’red herring’ in the
debate about the future development of HCE, which crucially depends on
changes in medical technology over time. Their conclusion stands in stark
contrast to na¨ıve predictions using raw HCE profiles from descriptive statis-
tics.
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The ’red herring’ hypothesis has given rise to several conceptual and
methodological criticisms [cf. Salas and Raftery (2001), Dow and Norton
(2002), Seshamani and Gray (2004a), Seshamani and Gray (2004b), and
Stearns and Norton (2004)]. Zweifel, Felder and Werblow (2004) addressed
these issues with a more sophisticated econometric analysis that included
not only deceased individuals but also survivors. They conclude that the
’red herring’ hypothesis argument still stands.
This paper seeks to contribute to the debate in two ways. First, it com-
prehensively addresses the estimation issues that have been raised since the
publication of the ZFM article. These issues are important because econo-
metric specification determines the split between the morbidity and mortality
component of HCE. The second contribution is consistency. In fact, ZFM
were able to purgeHCE from its mortality component by a associatingHCE
wit TTD. This amounts to treating the mortality component of HCE as a
residual that does not deserve further analysis when it comes to forecasting
aggregate HCE. This contribution seeks redress the balance by studying the
dynamics governing the development of the aggregate mortality component.
The following four points will be addressed.
1. Estimation based on a sample of dying and surviving individuals runs
the risk of underestimating the influence of TTD on HCE. This is
because information about TTD is only available for those individuals
who died within the observation period. For survivors, the variable
TTD and hence the dummy variable ’one year to death’ (death1, see
section 2) is unknown. Therefore, death1 takes on a ’missing value’ for
survivors, causing them to be excluded from the estimation. Replacing
missing values of death1 with zeroes, one implicitly assumes that these
individuals will not die one year later. But obviously, some survivors
will die in the following year. Thus, replacing missing values by ze-
roes shifts too much HCE to the morbidity component, resulting in
an upward (downward) bias of the death1 coefficient pertaining to the
morbidity (mortality) component of HCE.1
In case TTD is not measured using dummy variables but rather a
single variable measuring distance to death, one needs to replace un-
defined values by large values implying that survivors will not die in
1An empirical comparison of the specification proposed here with replacing missing
values by zeroes shows that the bias is small in the present dataset. However, this need
not to be the case in general.
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the foreseeable future. Assigning a large arbitrary value to TTD, as
in Zweifel et al. (2004) and Breyer and Felder (2004), causes TTD to
be measured with considerable error (survivors constituting the great
majority of observations), which again imparts a downward bias to the
coefficient of TTD in the estimation equation.
There are at least three ways to deal with this problem. The first, es-
poused by ZFM as well as by Seshamani and Gray (2004b), is to limit
the sample to deceased individuals only. While this approach may be
appropriate when the focus of research is on HCE of the elderly, it
runs into problems when the objective is to forecast HCE of an en-
tire population, which requires full age-expenditure profiles. Since the
present paper revolves around forecasting, its data base must contain
both survivors and deceased individuals.
The second solution, proposed by Stearns and Norton (2004), is to
replace all undefined values by zeroes and to introduce an additional
variable, ’time to censoring’. The considerable merit of this approach
lies in the fact that it uses an indicator of the measurement error con-
tained in TTD for inclusion in the regression, thus purging the error
term in the equation of that measurement error. However, it suffers
from two weaknesses. First, ’time to censoring’, being just an indica-
tor of the measurement error contained in TTD, may fail to effectively
perform its purging function. Second, it is highly collinear with mea-
sured TTD, causing a severe loss of precision in the estimation of all
regression coefficients.
A third alternative, advocated here, is to delete all observations with an
undefined value for deatht and hence TTD, where t defines the number
of years for which survivors and deceased are distinguished in the es-
timation. This amounts to excluding the last t annual observations of
all survivors in the sample. This is the only way to deal with undefined
values that avoids the dubious construction of a proxy variable. The
concomitant loss of sample size does not have much relevance in view
of the huge size of the data base used here (cf. section 2). However,
since TTD may well depend e.g. on technological change in medicine
during the years deleted, there is some risk of bias, which would result
in an underestimation of the influence of TTD.
2. An important econometric issue is the fact that a substantial number
of individuals have zero HCE. This calls either for sample selection
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modeling [typically of the Heckit variety as in ZFM, with the risk of in-
curring identification problems, as argued by Salas and Raftery (2001)].
The alternative, pursued here, is to specify a two-part model. In the
first part, the probability of nonzero HCE is estimated. In the second
part, the amount of HCE is estimated for all individuals with positive
HCE.
3. HCE values usually are heavily skewed. Transforming the data is a
common procedure for handling this problem. However, this entails
the difficulty of retransformation after estimation [cf. Manning and
Mullahy (2001)]. The solution proposed in this paper is to estimate a
generalized linear model.
4. Turning to the forecasting of HCE, consistency is introduced in the
following way. With increasing life expectancy, the mortality compo-
nent of HCE (also called ’cost of dying’) will accrue at a higher age.
Thus, na¨ıve forecasts of HCE that fail to account for this shift of the
mortality component have an upward bias, simply because the share
of deathbound at a given age will be smaller than today. This is the
ZFM argument. However, ZFM neglected the future dynamics of the
aggregate mortality component. Indeed, the cost of dying will increase
once the baby boomers reach dying ages. Thus, while ZFM are cor-
rect in their distinction between morbidity and mortality components
of HCE, they fail to carry it over to the forecasting of future aggregate
HCE, committing an inconsistency that is redressed below.
The remainder of this paper is organized as follows. In section 2, the data
and econometric methods applied are presented. Section 3 contains the es-
timation results and presentations of corresponding age profiles of HCE.
In section 4, both the morbidity and mortality components of HCE are
combined to derive forecasts of future HCE that are fully consistent with
estimation results. Section 5 shifts the focus to aggregate HCE and some
dynamic issues and section 6 contains concluding remarks.
2 Data and econometric model
The present study is based on a data set comprising about 450,000 members
of a major Swiss sickness fund. Spanning the years 1997 through 2004, it
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results in a sample of more than 3.7 million observations. Throughout, HCE
is defined as per capita healthcare expenditure that is reimbursed by social
insurance.2
In Switzerland health insurance is mandatory but individually contracted
(contrary to most other countries including the United States, there is no
employer involvement). Premiums must not be risk-based but uniform for
all adults of a given insurer with residence in a given region. There is a risk
adjustment scheme designed to prevent risk selection by competing health
insurers. The minimum annual deductible is CHF 230 (starting 2004: CHF
300; 1 Swiss franc CHF=0.8 US$ at 2004 exchange rates), combined with
a copayment of 10 percent of HCE (capped at CHF 700 annually). Thus,
total out-of-pocket payments by an individual with a standard contract is
limited to a maximum of CHF 930 per year (effective 2004: CHF 1,000), or
some 1.5 percent of average income. Additionally, the insured may choose
deductibles of up to CHF 1,500 (starting 2005: CHF 2,500). Managed-
care (MC) contracts, viz. health maintenance organizations (HMO), preferred
provider organizations (PPO), and physician networks are also available.
There is a vivid debate about the effect of such non-conventional con-
tracts. It revolves around the issue of whether the substantial cost savings
achieved by MC are due to risk selection or due to innovations in the guise of
changed incentives. A recent study concludes that between one-third (physi-
cian networks) and two-thirds (HMO) of cost savings cannot be traced to
risk selection effects and therefore may reflect true innovation [Lehmann and
Zweifel (2004)]. Still, the choice of MC contracts or policies with higher de-
ductibles needs to be modeled in principle. In order to avoid the (difficult)
estimation of the pertinent selection mechanisms, all observations having de-
ductibles in excess of CHF 230 or a MC option were deleted from the sample.
As argued in the preceding section (item 1), since the indicators ’year
of death’ (death0), ’one year to death’ (death1) and ’two years to death’
(death2) of ’time to death’ (TTD) are to be used, the last three observations
of survivors are dropped in order to limit the amount of bias that can be
imparted by the measurement error contained in these indicators of TTD.
All these deletions leave 1,273,908 observations for estimation. On aver-
age, an individual has 4.5 observations, causing the data set to be of the panel
2HCE thus includes all ambulatory care outlays, about 20 percent of long-term care
expenditure (the rest being paid out of pocket and by public assistance), and no more
than 50 percent of hospital expenditure (since the cantons finance at least one-half of
these costs).
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type. This calls for a random-effects specification for two reasons. First, it
is important to control for unobserved heterogeneity caused by unobserved
health, which may be poorly approximated by the socioeconomic variables
available. Second, cohort and age effects can be disentangled in this way. The
fixed-effects alternative does not seem to be appropriate because explanatory
variables such as sex are time-invariant.
There is a significant number of observations where HCE does not exceed
the deductible.3 These individuals paid out of pocket or were not sick at
all. Accordingly, the first step of the two-part model is estimated using the
following random-effects probit model4
Pr(HCEi,t > Deductible) = Φ{α+ βXi,t + υi + i,t}, (1)
where Φ{·} denotes the standard normal distribution, Xi, t contains TTD
(represented by three variables death, death1, death2 indicating whether in-
dividual is 0, 1, 2 years away from death), age (up to cubic), a dummy
variable sexf for women, interaction terms involving age and sexf, plus a
set of dummy variables controlling for regional effects and calendar years.
This was necessary because morbidity and the level of HCE differ consider-
ably between regions, while yearly dummies reflect the state of the medical
technology. Moreover, all TTD variables are interacted with age, age2, sexf,
sexfage, and sexfage2 to allow for more flexibility in modeling the mortal-
ity component of HCE. Finally, υi is the random effect specific to insured
individual i, while i,t denotes the iid error term pertaining individual i in
year t.
In the second step of the two-part model, the amount of HCE|HCE >
Deductible is estimated using the same set of regressors as in the first part.
Since HCE is heavily skewed, estimated parameters may not be robust;
moreover, significance tests based on the normality assumption are inade-
quate. A Box-Cox test indicated that a log transformation results in the
best approximation to normality. However, standard estimation procedures
predict E(log(y)|x) rather than log(E(y)|x), calling for a difficult retrans-
formation after estimation.5 Alternatively, a generalized linear model with a
3HCE below the deductible is not consistently observed since consumers have no in-
centive to submit the bills.
4Choice of the appropriate model in this context is discussed in Seshamani and Gray
(2004a); Dow and Norton (2002); or Jones (2000).
5Duan’s smearing procedure to retransform the predicted values may be a solution, but
has desirable statistical properties only in absence of heteroscedasticity [cf. Duan (1983)].
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log-link may be estimated. The relationship between the conditional means
E(y|x) and variances V (y|x) of HCE and the regressors suggests using the
gamma distribution for the error term εi,t [making V (y|x) proportional to
[E(y|x)]2, cf. Manning and Mullahy (2001)],
HCEi,t|HCEi,t > Deductible = κ+ λXi,t + εi,t. (2)
Note that equation 2 does not include an individual random effect; however,
the correlation of an individual’s observations over time is taken into account
by computing robust standard errors. As stated in Hardin and Hilbe (2001),
this leads to unbiased and consistent estimates.
Recent research into the so-called Sisyphus syndrome [cf. Zweifel and Fer-
rari (1992); Zweifel et al. (2005); see also Frech and Miller (1999)] has found
that HCE does positively affect remaining life expectancy at the popula-
tion level, implying that TTD is endogenous to HCE. To avoid possible
simultaneity bias, an instrumental variables regression was envisaged. The
instruments should ideally be correlated with death, but not with HCE.
However, there are no instruments at hand that could satisfy this require-
ments. Hospital days (contemporary or lagged), diagnostic information, and
state of health [derived from previous observations of HCE as in Lehmann
and Zweifel (2004)] do not qualify since they are heavily correlated with
HCE. Education is known to affect remaining life expectancy at a given
age, but unfortunately is not included in the data.
Endogeneity of TTD certainly is a problem in a time series context since
it likely reflects advances in medical technology (which is captured by a series
of dummy variables, not shown in table 1 below). Due to a comprehensive
uniform list of benefits in mandatory health insurance, all Swiss citizens have
access to the same medical technology both at a given point of time and over
time. This means that differences in individual HCE are not related to
differences in technology applied (and hence TTD). Finally, even if HCE
and medical technology do prolong life, in many cases the effect is months
rather than years, causing the increase in life expectancy not to be reflected
in the yearly observations analyzed here. In sum, one has reason to conclude
that the endogeneity of TTD is greatly mitigated in the present context and
that failure to perform an instrumental variable estimation should not cause
much bias.
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3 Estimation results
The probit estimates of equation 1 (shown in the first three columns of ta-
ble 1) exhibit extremely large z values of age, age2, age3, and their interaction
terms with sexf. On the other hand, death0, death1, death2 and their inter-
action terms often fall short of standard significance levels, likely because of
multicollinearity with age-related regressors. However, they are jointly sig-
nificant, as indicated by a series of Wald tests. In figure 1, the estimated
relationship between age and the probability of having HCE > Deductible
is plotted for both genders.
As expected, this probability declines with age, reaches a minimum (at
age 25 for women and 30 for men), and then increases again. At ages beyond
75, both women and men are very likely to have HCE > Deductible.
Figure 1: Probability of having HCE > Deductible
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The estimation results for the second part of the model (equation 2, cf.
the last three columns of table 1), again show most regressors involving age
to have high z values. However, several regressors fall short of conventional
significance levels, likely due to two different reasons. First, there indeed
may not be a relationship between the regressor and HCE. For example, this
seems to be the case for age3 (but not for sexfage3). A regression omitting this
particular variable indicated that the parameters of age and age2 remained
stable, suggesting age3 does not influence HCE of men. A second reason
for lack of significance might be multicollinearity. While multicollinearity
does not result in biased parameters, it causes estimated standard errors to
strongly increase. Thus, in the presence of multicollinearity, the probability
of type II errors looms large. For example, omitting age3 results in the
parameter of age2 having a much higher z value than shown in table 1.
This finding is confirmed by a Wald test, which indicates that the coeffi-
cients pertaining to three of the age-related regressors jointly are not signifi-
cantly different from the first two [H0 : βage+ βage2+ βage3 = βage+ βage2 need
not be rejected, χ2(1) = 0.09, Prob > χ2 = 0.7634]. Since the coefficients of
both the first two and also of all three age-related terms are jointly different
from zero, a quadratic specification for estimating the relationship between
age and HCE for men is sufficient.
For women, however, the cubic specification seems to be more adequate
since H0 : βsexfage+ βsexfage2+ βsexfage3 = βsexfage+ βsexfage2 is rejected with
very low error probability [χ2(1) = 248.89, Prob > χ2 = 0.0000].
With respect to the occurrence of death among men, most regressors,
including interactions with age-related variables, are significantly different
from zero. Moreover, the significance of these regressors differs between
men and women [i.e. H0 : βdeathtsexf+ βdeathtsexfage+ βdeathtsexfage2 = 0 may
be rejected with error probability Pr < 0.008], justifying the specification
presented in table 1 which allows for gender-specific HCE patterns.
The estimation results of table 1 may now be used to compute the ex-
pected age-expenditure profiles plotted in figure 2. The expected value of the
morbidity component (CMORB) of HCE (as a function of age) is obtained
by weighting estimated HCE [E(HCE|HCE > 230)] from equation 2 with
the estimated age-specific probability of having HCE exceeding CHF 230.
Dropping i for simplicity [cf. equation 1], one has
CMORB = E(HCE|HCE > 230|deatht = 0) ∗ Pr(HCE > 230). (3)
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Table 1: Estimation results
First part, equation 1 Second parta), equation 2
Variable Coeff SE z Coeff SEb) z
age -0.1598 0.0017 -92.20 0.0416 0.0020 20.44
age2 0.0034 0.0000 71.02 -0.0002 0.0001 -4.10
age3 0.0000 0.0000 -47.19 0.0000 0.0000 0.63
sexf -0.6183 0.0233 -26.54 -0.2597 0.0210 -12.36
sexfage 0.0982 0.0024 41.69 0.0311 0.0025 12.53
sexfage2 -0.0019 0.0001 -29.56 -0.0009 0.0001 -12.74
sexfage3 0.0000 0.0000 19.75 0.0000 0.0000 13.28
death0 0.3893 0.5393 0.72 2.3152 0.3853 6.01
death0age 0.0179 0.0181 0.99 -0.0044 0.0109 -0.40
death0age
2 -0.0001 0.0001 -0.73 -0.0001 0.0001 -1.44
death0sexf 1.6638 1.1414 1.46 0.0847 0.5610 0.15
death0sexfage -0.0553 0.0352 -1.57 0.0147 0.0155 0.95
death0sexfage
2 0.0004 0.0003 1.60 -0.0002 0.0001 -1.89
death1 -0.8932 0.4396 -2.03 3.2513 0.5056 6.43
death1age 0.0501 0.0145 3.46 -0.0484 0.0145 -3.33
death1age
2 -0.0004 0.0001 -3.57 0.0002 0.0001 2.20
death1sexf 1.6041 0.8365 1.92 -1.3660 0.7519 -1.82
death1sexfage -0.0597 0.0259 -2.30 0.0556 0.0209 2.66
death1sexfage
2 0.0005 0.0002 2.51 -0.0005 0.0001 -3.22
death2 -1.0802 0.4973 -2.17 3.5398 0.8664 4.09
death2age 0.0506 0.0163 3.10 -0.0680 0.0244 -2.79
death2age
2 -0.0004 0.0001 -3.19 0.0004 0.0002 2.29
death2sexf 1.0765 0.8432 1.28 -1.0765 1.0186 -1.06
death2sexfage -0.0496 0.0265 -1.87 0.0490 0.0284 1.72
death2sexfage
2 0.0004 0.0002 2.19 -0.0004 0.0002 -2.17
constant 2.3208 0.0229 101.41 6.1659 0.0252 244.96
Observations 1,273,908 1,009,286
Groups 285,168 225,952
Log-Likelihood: -508,993.24 AIC: 17.34
Wald Pr(χ2 > 0) 0.0000
a) Estimation using the Newton-Raphson algorithm.
b) Estimation using the Huber-White sandwich estimator.
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All dummy variables reflecting death and TTD are set equal to zero when
computing E(HCE|HCE > 230|deatht = 0) in equation 3, ensuring that
CMORB is uncorrelated with the mortality component of HCE. On the
whole, CMORB (solid lines in figure 2, starting at values close to zero) in-
creases with age for both sexes. For women, CMORB generally runs higher
and increases more steadily, while for men up to age 30, there seems to be
no relationship between age and CMORB. At ages beyond 80, women (but
not men) exhibit exponentially increasing CMORB. This important difference
can be detected thanks to the cubic specification, which allows for additional
flexibility.
The mortality component CMORT of expected HCE is calculated as a
function of age as follows. First, the cost of dying COD is defined as the
excess of predicted HCE given that the individual dies, summed over the
last three years of life. Thus, COD is given by
COD =
2∑
t=0
[E(HCE|HCE > 230|deatht = 1) (4)
−E(HCE|HCE > 230|deatht = 0)].
Next, COD is weighted by age-specific mortality rates Pr(MORT ) whose
values are observed for the year 2000 and forecast for 2001 to 2030. The
age-dependent mortality component of expected HCE is thus given by
CMORT = COD ∗ Pr(MORT ) (5)
In figure 2 only COD as defined in equation 4 is shown for the last
year of life. Interestingly, the graphs tend to be inversely U-shaped, with
a peak at age 54 for men and at age 41 for women, HCE amounting to
approximately CHF 21,000 for women and CHF 14,500 for men, respectively.
The conditional mortality component of HCE of the deceased (COD) can
now be compared to the morbidity component pertaining to the survivors. In
keeping with previous findings [Lubitz and Riley (1993); Zweifel et al. (1999)],
COD is several multiples of CMORB at most ages. However, since COD
declines past ages 54 (men) and 41 (women), the factor of proportionality
is not a constant but varies with age, an observation also made by Zweifel
et al. (2004).
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Figure 2: The morbidity (CMORB) component of HCE and the cost of
dying (COD) as a function of age, in CHF (2000)
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These findings are consistent with economic theory, which predicts that
the relationship between the value of a statistical life and age is inversely
U-shaped, with a maximum value around the age of forty [Schelling (1968),
Shepard and Zeckhauser (1982)]. Therefore, willingness to pay for survival
(which is reflected in COD if physicians act as reasonably good agents of
their patients) should exhibit the same pattern. This prediction has been
empirically confirmed by several authors [cf. Carthy, Chilton and Cookson
(1999), Jones-Lee, Hammerton and Philips (1985), Mount, Weng and Schulze
(2000)].
Estimated CMORB and CMORT sum up to predicted healthcare expen-
diture ĤCE. Comparison of ĤCE with country-wide age-specific HCE
published by the Swiss risk adjustment fund may serve as a check on the ex-
13
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Figure 3: Country-wide and estimated age profiles of HCE, using observed
deaths (in CHF, 2000)
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ternal validity of the two-part-model estimated. As can be seen from figure 3,
the profiles match quite well.6
6Using the quadratic rather than the cubic specification of equation 2, one obtains
ĤCE values that do not fit as well as in figure 3, especially for women at ages around 30
and at high ages, thus confirming the need for a cubic specification.
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4 What impact of aging on future health care
expenditure?
The claim of ZFM is that neglecting the distinction between the morbidity
and mortality component of HCE results in an overestimation of the impact
of aging of the population on future HCE. Since then, a consensus has
evolved that the mortality component must be controlled for when estimating
HCE profiles designed to serve as a basis for prediction. Thus, forecasting
future HCE according to ZFM accounts to simply extrapolating equations 3
and 5, with Pr(MORT ) adjusting for the expected increase in longevity.
However, this procedure ignores that consistency requires the not only the
morbidity but also mortality component to be controlled for changes in the
composition of population. Failure to do so may be consequential when the
number of deaths will increase in the future (at present, because the baby
boomers are coming of age). This phenomenon is of relevance not only for
the United States but for other industrial countries as well, among them
Switzerland. While crude Swiss mortality rates decreased (or at least were
stable) until the year 2000, they are predicted to increase from a current
value of below 900 per 100,000 to more than 1,200 by 2050.
Incorporating the mortality component into forecasts of HCE therefore
must cause a surge in future HCE that was not accounted for by ZFM, who
implicitly assumed the mortality rate to remain constant. In the consistent
approach proposed here, this failure is corrected as follows. Predicted ĤCEt
(t = 2000, ..., 2030) is adjusted for changes in the future cohort structure of
the population by calculating
ĤCEt =
1
Pt
n∑
c=1
[pc,t ∗ CMORBc,t] + 1
Pt
n∑
c=1
[dc,t ∗ CODc,t] (6)
Pt =
n∑
i=1
pc,t.
Here, Pt is the number of individuals alive in future period t, composed
of the n cohorts comprising pc,t people, of which dc,t die,
7 CMORB denotes
7These numbers are available from the demographic forecasts provided by Mu¨nz and
Ulrich (2001).
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the predicted per capita cost of morbidity, and COD stands for the cost
associated with dying as defined in equation 4. By definition of the aging ef-
fect, age-specific CMORB and COD are held constant over time (CMORBc,t =
CMORBc,2000 and CODc,t = CODc,2000). Thus, any future change in pref-
erences and medical technology that might influence CMORB and COD are
assumed away in order to filter out the pure aging effect. In relative terms,
the pure aging effect (A) can now be defined as
A = ĤCEt
HCE2000
, t = 2000, ..., 2030. (7)
The extent to which ĤCE differs from a na¨ıve forecast that does not dis-
tinguish between the morbidity and mortality component of HCE crucially
depends on how the cost of dying varies with age. If COD had a flat profile,
the na¨ıve forecast, the ZFM approach, and the consistent approach advo-
cated here would converge since the mortality component would be largely
irrelevant. If however COD were to increase with age (which it does to some
extent, cf. the age profile of COD in figure 2), then the mortality component
of aggregate HCE will increase temporarily when the baby boomers cause a
rise in the number of deaths. In this case, the consistent forecasting approach
defined by equation 6 predicts an even more marked aging effect than either
the na¨ıve forecast or the ZFM approach.
The three forecasts are juxtaposed in figure 4. The na¨ıve forecast (which
fails to distinguish the morbidity and mortality components of HCE) results
in a pure aging effect that increases from 0.5 percentage points (pp) in 2000
to 0.8 pp by 2010 and approaches 0.7 pp by 2030 (0.72 pp on average p.a.).
The ZFM alternative (which distinguishes the two components but neglects
the impact of baby boomers on the mortality component of future HCE)
would predict no impact of aging on HCE, at least when using the flat,
age-invariant profiles estimated in ZFM. However, the consistent approach
adopted here results in a pure aging effect of 0.5 pp annually over the period
2000 to 2030.
The alternative proposed in this paper (which consistently distinguishes
between the morbidity and the mortality components not only in estimation
but also in forecasting) results in a pure aging effect of 0.43 pp in 2000 that
reaches a maximum of 0.62 pp around 2010 and converges to 0.48 pp by
2030 (0.54 pp on average p.a.). This difference needs to be put in proper
perspective. Compared to the 5 percent growth rate observed in Swiss HCE
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between 1996 and 2003, the question whether the aging of the population
accounts for 0.5 or 0.7 pp is not very relevant. The absolute differences are
not too impressive either. According to the na¨ıve forecast, aging would cause
HCE to increase from about CHF 2,200 in 2000 to CHF 2,700 by 2030. The
ZFM alternative predicts CHF 2,600. The consistent approach of this paper
leads to predicted HCE reaching CHF 2,500 by 2030. Therefore, the effect
of aging on HCE is relatively small in all scenarios, especially if compared
with an extrapolation based on a 5 percent growth rate which would have
HCE increase to CHF 9,500.
On the whole, these findings serve to qualify the conclusion reached by
ZFM and reiterated by Zweifel et al. (2004), who in their re-examination of
ZFM state that the ”na¨ıve estimation that does not control for proximity to
death will grossly overestimate the effect of population ageing on aggregate
health care expenditure”. This statement must be seen in relation to the
relatively small impact of aging on future HCE. Only if future HCE growth
were to fall markedly below the high values experienced in the recent past
would the distinction between the morbidity and mortality components of
HCE make a significant difference.
On the aggregate level, the picture looks quite different. According to
the consistent approach, aggregate HCE in mandatory health insurance will
increase by a third, from CHF 15.5 in 2000 to 20 billion in 2030 solely due
to demographic changes. Since in Switzerland HCE is financed by flat rate
premiums, the younger will have to bear a substantial part of the costs in-
duced by aging. While the under 60 year old were supporting the elderly
with CHF 4 billion in 2000, in 2030 it will be CHF 6 billion, an increase by
50 percent (in prices of 2000). Thus, even if the aging effect is quite small in
terms of per capita HCE, the distributional effect is significant.
5 Discussion
One has to keep in mind that the preceding analysis is based on a static
concept. Age profiles are held constant when computing the aging effect.
This is not a simplification but rather—by definition—a necessity in order
to isolate the consequences of aging. Only the demographic structure of the
population is allowed to change.
However, age profiles of HCE have been changing in the past and will
most certainly also change in the future. There are two competing hypothe-
17
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Figure 4: Contribution of aging to future growth of HCE (2000-2030)
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ses. The first—compression of morbidity—goes back to Fries (1980) and
postulates a compression of individual HCE towards the end of life. People
will become healthier over time, thus reducing their HCE until they enter
the terminal phase of life. Olshansky, Rudberg, Carnes, Cassel and Brady
(1991) on the other hand claim that people at all ages will get more medical
treatment, resulting in an upward shift of the age profiles, possibly accompa-
nied by an increase of the age gradient. This second hypothesis is known as
the expansion of morbidity. If true, a steepening of age profiles will indirectly
increase the aging effect and HCE growth in an aging society.
In Switzerland, a significant steepening of age profiles has been observed
since the new health insurance law was put in force in 1996. While growth
of HCE to 2005 was below 50 percent for those under 50 years, it was up
to 70 percent for the oldest age categories (cf. figure 5). This early age
where steepening begins contributes evidence in favor of the expansion of
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Figure 5: Steepening of age profiles of HCE, Switzerland (1996-2005)
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morbidity hypothesis advanced by Olshansky et al. (1991). There is also a
theoretical argument in favor of the expansion hypothesis. HCE certainly
are inputs in the production of health and health has to be viewed an out-
put. Fries’ hypothesis is based on an improvement of the output which in
turn also requires more inputs and therefore more HCE. For many other
countries, a steepening of age profiles has been observed as well.8 Cutler
and Meara (1999), analyzing Medicare data for the period 1985 to 1995,
find that this steepening is due to an increase of post-acute services such as
home healthcare and skilled nursing care. Based again on Medicare data,
8For Belgium, cf. Van Tielen, Peys and Genaert (1998); for France, Australia and
other OECD-countries, cf. Jacobzone (2002); for Germany, cf. Buchner (2001); for the
United Staates of America, cf. Fuchs (1998), Cutler and Meara (1999); for Switzerland,
cf. Steinmann and Telser (2005).
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Fuchs (1998) concludes that the increasing age gradient of HCE is mainly
due to technological progress. Therefore, it might become even steeper in
the wake of technological change in medicine, reinforcing this indirect aging
effect. In their international comparison, Seshamani and Gray (2002) report
mixed evidence, suggesting that age-specific growth of HCE is linked to the
type of healthcare system. Since an increasing age gradient of HCE was
not observed in England and Wales and Canada with their National Health
Services, this constancy may be interpreted as the reflection of age-based
rationing (which is typically not imposed by insurance-based systems). This
leads to the conclusion that institutional characteristics cause differences in
age-specific growth of HCE.
If the steepening of age profiles were to continue at the pace observed
between 1996 an d 2005, forecast per capita HCE in Switzerland would be
more than three times as large as the 0.55 pp. estimated based on constant
age profiles, resulting in yearly growth rates of 1.7 pp. between 2000 and
2030. Aggregate HCE will almost double, reaching CHF 28 billion in 2030
(compared to 20 billion with constant age profiles). This figure still excludes
HCE growth that is independent of age. While both per capita and ag-
gregate HCE would be higher still, the distribution of costs and benefits of
HCE between young and old would not be affected.
6 Conclusions
Aging will not contribute much to future growth of per capita healthcare
expenditure (HCE). When computing the aging effect in a na¨ıve way, i.e.
neglecting the distinction between the morbidity and mortality component
of HCE as proposed by Zweifel et al. (1999), HCE growth in Switzerland
is predicted to hover around 0.7 percentage points per annum over the next
25 years. If proximity to death is controlled for when estimating the age
profile of the morbidity component while neglecting the likely dynamics of
the mortality component [as Zweifel et al. (1999) implicitly do], the predicted
contribution of aging to HCE growth shrinks to 0.5 points. Finally, the fully
consistent approach, proposed in this paper, is to use the same decomposition
developed in estimation also for forecasting. This means taking into account
the fact that the cost of dying will be weighted by an increasing mortality
rate due to the baby boomers’ coming of age. This causes the predicted
contribution of aging to HCE growth to increase back to 0.55 percentage
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points per annum. Thus, a fully consistent decomposition approach leads to
a result that does not substantially modify a na¨ıve extrapolation.
There is, however, concern that these projections underestimate the con-
sequences of of aging. First, even if HCE growth due to aging will be quite
small in per capita terms, on the aggregate level HCE will increase from
CHF 15 billion to 20 billion in 2030 (1 CHF=0.8$). Second, a steepening of
age profiles has been observed in the past. If this process were to continue,
an even larger share of HCE will be devoted to the elderly, causing the fi-
nancial burden on the younger generations to increase. Third, age profiles
for long-term care (LTC) are known to be even steeper than for the other
components of HCE [Werblow, Felder and Zweifel (2006)]. Therefore, the
aging effect is expected to be larger for LTC. Since, in the case of Switzer-
land, only 20 percent of LTC is financed by mandatory health insurance, the
full extent of aging will be underestimated in this study.
There is an additional channel of influence that may reinforce the impact
of aging on future HCE. It is the so-called Sisyphus syndrome which claims
that aging shifts voting power to the elderly who in turn seek—through the
democratic process—to allocate more and more resources to public health
care [Zweifel and Ferrari (1992), Zweifel et al. (2005)]. This means that the
young members of society will increasingly have to carry the burden of aging.
Since they also have to finance old-age pensions for retired beneficiaries whose
remaining life expectancy continues to increase, aging may well become a
major challenge.
References
Barnato, A.E., A.M. Garber, Ch.R. Kagay and M.C. McClellan (2006).
Trends in the Use of Intensive Procedures at the End of Life. Forum
for Health Economics & Policy, Forum: Frontiers in Health Policy Re-
search, 4(5).
Breyer, F. and S. Felder (2004). Life Expectancy and Health Care Expen-
ditures: A New Calculation for Germany Using the Costs of Dying.
Working Paper 452, DIW Berlin.
Buchner, F. (2001). Versteilerung von Ausgabenprofilen in der Kranken-
versicherung. In G. Ga¨fgen and P. Oberender, eds., Gesund-
heitso¨konomische Beitra¨ge, volume 37. Nomos, Baden-Baden.
21
Steinmann et al.: Aging and Future Healthcare Expenditure
Carthy, T., S. Chilton and R. Cookson (1999). The Valuation of Benefits
of Health and Safety Control: Final Report to the Health and Safety
Executive. Health and Safety Executive, London.
Cutler, D. and E. Meara (1999). The Concentration of Medical Spending:
An Update. Working Paper 7279, NBER.
Dow, W. H. and E. C. Norton (2002). The Red Herring that Eats Cake:
Heckit versus Two-part Model Redux. Triangle Health Economics Work-
ing Paper Series , 1.
Duan, N. (1983). Smearing Estimate: A Nonparametric Retransformation
Method. Journal of the American Statistical Association, 78(383):605–
610.
Frech, III., H. E. and Jr. Miller, R. D. (1999). The Productivity of Health
Care and Pharmaceuticals: An International Comparison. The AEI
Press, Washington D.C.
Fries, J. F. (1980). Aging, Natural Death, and the Compression of Morbidity.
New England Journal of Mededicine, 303(3):130–135.
Fuchs, V. R. (1998). Health Care for the Elderly: How Much, Who will Pay
for It? Working Paper 6755, NBER.
Gerdtham, U. G., B. Jo¨nsson, M. MacFarlan and H. Oxley (1998). The
Determinants of Health Expenditure in the OECD Countries: A Pooled
Data Analysis. In P. Zweifel, ed., Health, the Medical Profession, and
Regulation. Developments in Health Economics and Public Policy, vol.
6 , 113–34. Kluwer Academic, Boston and Dordrecht.
Gerdtham, U. G., J. Søgaard, F. Andersson and B. Jo¨nsson (1992a). An
Econometric Analysis of Health Care Expenditure: A Cross-Section
Study of the OECD Countries. Journal of Health Economics , 11(1):63–
84.
Gerdtham, U. G., J. Søgaard, B. Jo¨nsson and F. Andersson (1992b). A
Pooled Cross-Section Analysis of the Health Care Expenditures of the
OECD Countries. In P. Zweifel and III. Frech, H. E., eds., Health Eco-
nomics Worldwide. Developments in Health Economics and Public Pol-
icy Series, vol. 1, Norwell, Mass , 287–310. Kluwer Academic, Boston
and Dordrecht.
22
Forum for Health Economics & Policy, Vol. 10 [2007], Iss. 2, Art. 1
DOI: 10.2202/1558-9544.1041
Getzen, T.E. (1992). Population Aging and the Growth of Health Expendi-
tures. Journal of Gerontology , 47:98–104.
Guralnik, J.M., A.Z. LaCroix, L.G. Branch, S.V. Kasl and R.B. Wallace
(1991). Increasing Longevity and Medicare Expendituresm. American
Journal of Public Health, 81(4):443–447.
Hardin, J. and J. Hilbe (2001). Generalized Linear Models and Extensions .
Stata Press, College Station.
Hitiris, T. and J. Posnett (1992). The Determinants and Effects of Health
Expenditure in Developed Countries. Journal of Health Economics ,
11:173–181.
Jacobzone, S. (2002). Healthy Ageing and the Challenges of New Tech-
nologies: Can OECD Social and Health-Care Systems Provide for the
Future? In Healthy Ageing and Biotechnology, Policy Implications of
new Research, 37–53. OECD.
Jones, A. (2000). Health Econometrics. In Anthony J. Culyer and Joseph P.
Newhouse, eds., Handbook of Health Economics , volume 1A, 265–343.
Elsevier, Amsterdam, London, New York, Oxford, Paris, Shannon,
Tokyo.
Jones-Lee, M. W., M. Hammerton and P. R. Philips (1985). The Value of
Safety: Results of a National Survey. Economic Journal , 95:49–72.
Lee, R. and T. Miller (2002). An Approach to Forecasting Health Expendi-
tures, with Application to the U.S. Medicare System. Health Services
Research, 37(5):1365–1386.
Lehmann, H. and P. Zweifel (2004). Innovation and Risk Selection in Deregu-
lated Social Health Insurance. Journal of Health Economics , 23(5):997–
1012.
Leu, R. E. (1986). The Public-Private Mix and International Health Care
Costs. In A. J. Culyer and B. Jo¨nsson, eds., Public and Private Health
Services: Complementarities and Conflicts , 41–63. Blackwell, Oxford
and New York.
23
Steinmann et al.: Aging and Future Healthcare Expenditure
Lubitz, J. D. and G. F. Riley (1993). Trends in Medicare Payments in the
last Year of Life. New England Journal of Medicine, 328:1092–1096.
Lubitz, J.D., J. Beebe and C. Baker (1995). Longevity and Medicare Expen-
ditures. The New England Journal of Medicine, 332(15):999–1003.
Lubitz, J.D. and R.T. Prihoda (1984). he Use and Costs of Medicare Services
in the Last Two Years of Life. Health Care Financing Review , 5(3):117–
131.
Manning, W. G. and J. Mullahy (2001). Estimating Log Models: To Trans-
form or not to Transform? Journal of Health Economics , 20:461–497.
Mount, T., W. Weng and W. Schulze (2000). Automobile Safety and the
Value of Statistical Life in the Family: Valuing Reduced Risk for Chil-
dren, Adults and the Elderly. Working paper, United States Environ-
mental Protection Agency.
Mu¨nz, R. and R. Ulrich (2001). Alterung und Migration: Alternative de-
mographische Szenarien fu¨r die Schweiz . Avenir Suisse.
O’Connell, J. (1996). The Relationship between Health Expenditures and the
Age Structure of the Population in OECD Countries. Health Economics ,
5:573–578.
OECD (1987). Financing and Delivering Health Care: A Comparative Anal-
ysis of OECD Countries . Paris.
Olshansky, S. J., M. A. Rudberg, B. A. Carnes, B. A. Cassel and J. A. Brady
(1991). Trading off Longer Life for Worsening Health: The Expansion
of Morbidity Hypothesis. Journal of Aging and Health, 3(2):194–216.
Salas, C. and J. P. Raftery (2001). Econometric Issues in Testing the
Age Neutrality of Health Care Expenditure. Health Economics Letters ,
10:669–671.
Schelling, T. C. (1968). The Life You Save May be Your Own. In S. B.
Chase, ed., Problems in Public Expenditure Analysis . Brookings Insti-
tution, Washington, DC.
Seshamani, M. and A. Gray (2002). The Impact of Ageing on Expenditures
in the National Health Service. Age and Aging , 31:287–294.
24
Forum for Health Economics & Policy, Vol. 10 [2007], Iss. 2, Art. 1
DOI: 10.2202/1558-9544.1041
— (2004a). Ageing and Health-care Expenditure: The Red Herring Argu-
ment Revisited. Health Economics , 13:303–314.
— (2004b). A Longitudinal Study of the Effects of Age and Time to Death
on Hospital Costs. Journal of Health Economics , 23:217–235.
Shepard, D. S. and R. J. Zeckhauser (1982). Life-Cycle Consumption and
Willingness to Pay for Increased Survival. In M. W. Jones-Lee, ed., The
Value of Life and Safety , 95–141. North-Holland Publishing Company,
Amsterdam, New York, Oxford.
Stearns, S. C. and E. C. Norton (2004). Time to Include Time to Death?
The Future of Health Care Expenditure Predictions. Health Economics ,
13:315–327.
Steinmann, L. and H. Telser (2005). Gesundheitskosten in der alternden
Gesellschaft - Wieso nicht die Zunahme a¨lterer Menschen, sondern
falsche Anreize das Gesundheitswesen unter Druck setzen. (Health Costs
in the Aging Society). Verlag NZZ, Zu¨rich.
Van Tielen, R., F. Peys and J. Genaert (1998). The Demographic Impact
on Ambulatory Pharmaceutical Expenditure in Belgium. Health Policy ,
45:1–14.
Werblow, A., S. Felder and P. Zweifel (2006). Population Ageing and Health
Care Expenditure: A School of ’Red Herrings’? Revision submitted to
Health Economics .
Zweifel, P., S. Felder and M. Meier (1999). Ageing of Population and Health
Care Expenditure: A Red Herring? Health Economics , 8(6):485–496.
Zweifel, P., S. Felder and A. Werblow (2004). Population Ageing and Health
Care Expenditure: New Evidence on the ”Red Herring”. Geneva Papers
on Risk and Insurance - Issues and Practice, 29(4):652–667.
Zweifel, P. and M. Ferrari (1992). Is there a Sisyphus Syndrome in Health
Care? In P. Zweifel and H. E. Frech III, eds., Health Economics World-
wide. Developments in Health Economics and Public Policy Series, Vol.
1, Norwell, Mass , 311–30. Kluwer Academic, Boston and Dordrecht.
25
Steinmann et al.: Aging and Future Healthcare Expenditure
Zweifel, P., L. Steinmann and P. Eugster (2005). The Sisyphus Syndrome
in Health Revisited. International Journal of Health Care Finance and
Economics , 5(2):127–145.
26
Forum for Health Economics & Policy, Vol. 10 [2007], Iss. 2, Art. 1
DOI: 10.2202/1558-9544.1041
